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Background: Hypoxia is a negative prognostic factor and this study investigated the 
relationship between hypoxia, hypoxia inducible factor 1 (HIF-1) and AKT signaling 
in head and neck squamous cell carcinoma (HNSCC) and non-small-cell lung cancer 
(NSCLC). Results/methodology: pAKT was induced by hypoxia (0.5% O2) in a part of 
HNSCC (3/4) and squamous (2/3) and adenocarcinoma (1/3) NSCLS lines. AKT-inhibitor 
MK-2206 reduced hypoxic HIF-1 signaling in most HNSCC cell lines. This reduction did 
not correlate with hypoxic induction of pAKT or with sensitivity to MK-2206 under 
hypoxia. Patient biopsies revealed a hypoxia-induced expression pattern of pAKT in 
HNSCC (n = 16), which was not observed in squamous cell (n = 34) or adenocarcinoma 
(n = 41) NSCLC. Conclusion: The interaction between hypoxia, HIF-1 and AKT signaling 
varies between tumor types and histologies, which could significantly affect response 
to targeted therapies.
Lay abstract: Hypoxia is the result of an imbalance between oxygen delivery and 
oxygen consumption, and hypoxic areas are a common feature in solid tumors, 
including head and neck and lung cancer. Hypoxia activates various signaling 
pathways that enhance the survival of tumor cells (e.g., HIF-1 and AKT) and is, 
therefore, an inherent negative factor for outcome. In this study, we show that 
the interaction between hypoxia and these pathways varies widely between tumor 
types and histologies. This variation could significantly affect response to treatments 
targeting hypoxia or these signaling pathways.
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Published online: 29 January 2016
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Hypoxia is a common feature of solid tumors 
and is an inherent negative factor for treat-
ment outcome [1]. The hypoxia-inducible fac-
tor 1 (HIF-1) pathway is an important cell 
survival pathway in hypoxic cells as it induces 
the transcription of numerous genes regulat-
ing cell proliferation, angiogenesis, glucose 
metabolism and apoptosis [2]. In addition to 
signaling via this hypoxia pathway, signaling 
via growth factor receptors plays an important 
role in hypoxic cell survival as well. Protein 
kinase B (AKT) is activated by hypoxia in 
various tumor types [3–7], and we have shown 
that phosphorylated AKT (pAKT) is predom-
inantly expressed in hypoxic regions of both 
head and neck cancer xenograft tumors and 
patient biopsies [8,9]. Moreover, data of our lab 
indicate that hypoxic, but not normoxic, head 
and neck cancer cells are sensitive to AKT inhi-
bition [9]. The interaction between hypoxia 
and the AKT pathway is also important for 
treatment response as hypoxia-induced resis-
tance to chemotherapy has been shown to be 
mediated via the AKT pathway [3,6,10].
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Multiple studies indicate that the interaction 
between the AKT pathway and HIF-1 signaling is 
important for hypoxic cell survival and hypoxia-
induced treatment resistance [11]. The AKT path-
way has been shown to enhance HIF-1 signaling by 
increasing HIF-1α protein levels [12–15]. Correspond-
ingly, expression of pAKT has been correlated with the 
expression of HIF-1α in patient biopsies of different 
tumor types, including invasive breast carcinoma [16] 
and non-small-cell lung cancer (NSCLC) [17]. How-
ever, not all studies support this hypothesis, that is, the 
AKT pathway is not activated by hypoxia in all tumor 
cell lines and does not always mediate HIF-1 activ-
ity [18–20]. The specific interaction between hypoxia, 
HIF-1 and AKT signaling in a tumor could play an 
important role in the response to various new treat-
ment strategies, including hypoxic modification and 
AKT pathway inhibitors. Hence, insight in the inter-
action between hypoxia and AKT signaling could help 
to optimize patient selection and consequently patient 
outcome.
In this study, we investigated the relationship 
between hypoxia, AKT activation and HIF-1 signaling 
in a head and neck squamous cell carcinoma (HNSCC) 
cell line panel. A panel of NSCLC lines consisting of 
both adenocarcinomas and squamous cell carcinomas 
was also studied to determine the variation between 
tumor types and histologies within one tumor type. 
Moreover, the effect of AKT inhibition on hypoxic cell 
survival was tested to increase the insight in the depen-
dence of hypoxic cell survival on AKT activity. Lastly, 
the expression pattern of pAKT was studied in patient 
biopsies from HNSCC and NSCLC to assess whether 
the observed in vitro relations between AKT activation 
and hypoxia are also observed in the clinic.
Material & methods
Cell lines
Four human HNSCC cell lines (UT-SCC lines, gen-
erated by R.G., University of Turku) and six human 
NSCLC cell lines (obtained from the ATCC) were 
used in this study. The characteristics of the cell lines 
are shown in Table 1. Cell lines were not further authen-
ticated or tested. Cells were cultured in T75 culture 
flasks, under humidified conditions (37ºC, 5% CO
2
). 
Cells were maintained in DMEM (HNSCC lines) or 
RPMI1640 (NSCLC lines) containing 2 mM l-glu-
tamine, 1% nonessential amino acids, 20 mM Hepes, 
10 units/ml penicillin, 10 units/ml streptomycin and 
10% fetal bovine serum.
Hypoxic incubation & MK-2206 treatment
To determine protein expression after hypoxia, cells 
were incubated under hypoxic conditions (0.5% O
2
, 
H35 hypoxystation, Don Whitley Scientific Ltd., West 
Yorkshire, UK) for 1 h, 4 h, 8 h, 16 h or 24 h. To 
determine protein expression after AKT inhibition, 
cells were treated overnight (16 h) with 0 or 2 μM 
MK-2206 (Selleckchem, Houston, TX, USA) under 
standard normoxic conditions and thereafter incu-
bated under normoxic conditions or under hypoxic 
conditions (0.5% O
2
, H35 hypoxystation, Don Whit-
ley Scientific Ltd., West Yorkshire, UK) for 4 h, 8 h 
or 16 h.
To assess cell survival after hypoxia and/or AKT-
inhibition, cells were seeded in 96-well plates. After the 
cells were allowed to attach overnight under standard 
normoxic conditions, 0, 0.5, 1, 2, 4 or 8 μM, MK-2206 
was added and cells were incubated under normoxic 
conditions or under hypoxic conditions (0.5% O
2
) for 
72 h. To prevent interference of hypoxia in the deter-
mination of cell survival with the cell-counting Kit-8 
assay (Sigma–Aldrich Chemie BV, Zwijndrecht, The 
Netherlands), cells were placed back into normoxic 
conditions before measurement of cell survival. Cell 
survival was measured 72 h after hypoxic incubation 
in HNSCC lines and 24 h after hypoxic incubation in 
NSCLC lines.
Western blot analysis
Cells were lysed in radioimmunoprecipitation assay 
(RIPA) buffer and protein was quantitated using a 
standard Bradford absorbance assay. Proteins were 
separated by SDS-PAGE and blotted onto polyvinyli-
dene fluoride (PVDF) membrane. Membranes were 
incubated with the appropriate primary antibod-
ies followed by incubation with horseradish peroxi-
dase (HRP)-conjugated antibodies. Finally, proteins 
were detected using chemiluminescence. Antibodies 
against the following antigens were used: HIF1-alpha 
(BD-Transduction Laboratories, San Jose, CA, USA), 
GLUT-1 (H-43; Thermo Scientific, Waltham, MA, 
USA), CAIX (D47G3; Cell Signaling Technology), 
pAKT(S473; Cell Signaling Technology), AKT 1/2/3 
(H-136; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), HRP-conjugated goat-antirabbit IgG (Cell 
Signaling Technology), HRP-conjugated goat-anti-
mouse IgG (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) and α-tubulin (Calbiochem, San Diego, 
CA, USA). Given the many intricacies in quantifying 
Western Blots, we chose only to make qualitative state-
ments on the intensities of the stainings.
Patient biopsies
Biopsies were obtained from 16 patients with 
stage I–IV squamous cell carcinoma of the oral cav-
ity or oropharynx planned for curative treatment with 
fractionated radiotherapy with or without concurrent 
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chemotherapy. Before onset of treatment, biopsies were 
taken for routine diagnostic purposes and additional 
biopsies were taken for multiple marker analyses. The 
latter were snap-frozen in liquid nitrogen and used in 
this study.
Fresh frozen biopsies of 75 NSCLC tumors of a total 
of 74 patients were included from a study described in 
detail by Meijer et al. [21]. Only tumors with the histol-
ogy of adenocarcinoma and squamous cell carcinoma 
were used for this study.
All patient studies were performed according to 
institutional ethical rules and regulations.
Immunohistochemical staining, image 
acquisition & analysis of tumor sections
To determine localization of protein expression in vivo, 
frozen tumor sections (5 μm) were thawed, fixed in 
acetone (4ºC) and rehydrated in phosphate-buffered 
saline (PBS). Tumor sections were stained for pAKT 
in combination with vessels. The antibody against 
pAKT(S473) was obtained from Santa Cruz Bio-
technology and the antihuman endothelium anti-
body PAL-E was obtained from Euro Diagnostica AB 
(Nijmegen, The Netherlands). pAKT was detected 
by incubation with Cy3-conjugated goat-antirabbit 
F(ab’)
2
 fragments (Jackson Immuno Research Labora-
tories Inc., West Grove, PA, USA), and PAL-E by incu-
bation with Alexa647-conjugated chicken-antimouse 
IgG (Molecular Probes, Leiden, The Netherlands). 
Stained sections were mounted in Fluorostab (ICN 
Pharmaceuticals, Inc, Zoetermeer, The Netherlands).
Stained tumor sections were scanned on a digital 
image processing system on a fluorescence microscope 
(Axioskop, Zeiss, Göttingen, Germany) and a com-
puter-controlled motorized stepping stage, using IPLab 
software. Each section was sequentially scanned at 100× 
magnification, yielding an image of pAKT-expression 
and an image of the vasculature (PAL-E).
One pseudocolored composite image was recon-
structed from the individual microscope images. Using 
this composite image and a hematoxylin-eosin stained 
tumor section, total tumor area was delineated and 
nontumor tissue, necrotic area and staining artifacts 
were excluded from the analysis. Thereafter, thresh-
olds for the fluorescence signals were interactively set 
at intensities where the steepest gradient occurred 
between background and foreground intensity levels, 
and gray value images were converted to binary images. 
To quantify the distribution of pAKT in relation to 
the vasculature, zones were chosen at increasing dis-
tances from the nearest vessel (0–50, 51–100, 101–150, 
151–200 and 201–250 μm). Using Image J software 
(NIH, Bethesda, MD, USA), the fraction positive for 
pAKT in each zone was calculated by dividing the zone 
area positive for pAKT by the total zone area. Zones 
with areas <200 pixels were excluded from the analysis.
Statistics
Statistical analyses were performed using Prism (Graph-
Pad Software, Inc., LA Jolla, CA, USA) or SPSS (SPSS, 
Chicago, IL, USA). p-values < 0.05 were considered 
significant. Synergism between hypoxia and MK-2206 
was determined by correcting the cell survival after 
hypoxia and MK-2206 by the effect of hypoxia alone. 
Differences between the effect of MK-2206 under 
normoxia and the corrected effect of MK-2206 under 
hypoxia (difference = supra-additive effect) were tested 
for significance using Mann–Whitney tests. Bonferroni 
Table 1. Overview of cell line characteristics and interaction between hypoxia, AKT and hypoxia inducible factor 1 
signaling.
Cell line Tumor type Histology type Hypoxic 
induction of 
pAKT
Downregulation of 
HIF-1 signaling by 
AKT inhibition
Enhanced sensitivity to 
AKT inhibition under 
hypoxia
UT-SCC5 HNSCC Squamous cell ++ - ++
UT-SCC15 HNSCC Squamous cell ++ ++ ++
UT-SCC24A HNSCC Squamous cell - ++ -/+
UT-SCC38 HNSCC Squamous cell ++ - -
H226 NSCLC Squamous cell + + ++
SW900 NSCLC Squamous cell + - ++
H520 NSCLC Squamous cell - - -
H522 NSCLC Adenocarcinoma + - -
HCC827 NSCLC Adenocarcinoma - - -
H1975 NSCLC Adenocarcinoma - - +
++: Strongly present; +: Present ; -/+: Marginal; -: Negative; HIF-1: Hypoxia inducible factor 1; HNSCC: Head and neck squamous cell carcinoma;  
NSCLC: Non-small-cell lung cancer; pAKT: Phosphorylation of AKT. 
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UT-SCC5 H226
SW900
H520
H522
HCC827
H1975
UT-SCC15
UT-SCC24
UT-SCC38
pAKT(S473)
AKT
α-tubulin
pAKT(S473)
AKT
α-tubulin
pAKT(S473)
AKT
α-tubulin
pAKT(S473)
AKT
α-tubulin
pAKT(S473)
AKT
α-tubulin
pAKT(S473)
AKT
α-tubulin
pAKT(S473)
AKT
α-tubulin
pAKT(S473)
AKT
α-tubulin
pAKT(S473)
AKT
α-tubulin
pAKT(S473)
AKT
α-tubulin
Hypoxia (0.5% O2)
0h 1h 4h 8h 16h 24h
Hypoxia (0.5% O2)
0h 1h 4h 8h 16h 24h
Hypoxia (0.5% O2)
0h 1h 4h 8h 16h 24h
Hypoxia (0.5% O2)
0h 1h 4h 8h 16h 24h
Hypoxia (0.5% O2)
0h 1h 4h 8h 16h 24h
Hypoxia (0.5% O2)
0h 1h 4h 8h 16h 24h
Hypoxia (0.5% O2)
0h 1h 4h 8h 16h 24h
Hypoxia (0.5% O2)
0h 1h 4h 8h 16h 24h
Hypoxia (0.5% O2)
0h 1h 4h 8h 16h 24h
Hypoxia (0.5% O2)
0h 1h 4h 8h 16h 24h
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correction was applied to correct for multiple testing. 
Correlations between parameters were assessed using 
the Spearman correlation test.
Results
pAKT is induced by hypoxia in HNSCC cells & to 
a lesser extent in NSCLC cells
We have shown before that hypoxia increases pAKT 
expression in two HNSCC cell lines [9]. To obtain 
insight into whether this is a more common phenom-
enon in HNSCC, we extended our cell panel to four 
HNSCC lines and determined the effect of hypoxia 
(0.5% O
2
) on pAKT levels in a time-dependent man-
ner (Figure 1A). In addition, six NSCLC lines were 
studied to explore the variation between tumor types 
and histologies; three squamous cell carcinoma lines 
(Figure 1B) and three adenocarcinoma lines (Figure 1C) of 
the lung were investigated. Characteristics of the cell 
lines are shown in Table 1.
As observed before, pAKT expression increased by 
incubation with 0.5% O
2
 in a time-dependent man-
ner in all HNSCC lines, except for UT-SCC24A. In 
UT-SCC5, -15 and -38, pAKT levels increased within 1 
h of hypoxic incubation, and decreased to levels observed 
in normoxic cells after 16 h. Although less evident, two 
out of three (H226 and SW900) squamous cell lines 
and one out of three (H522) adenocarcinoma lines of 
the lung showed upregulation of pAKT under hypoxia. 
Interestingly, both the HNSCC and the NSCLC cell 
lines that did not upregulate pAKT had already high 
levels of pAKT under normoxic conditions. In almost 
all cell lines a decrease of pAKT at later incubation 
times was seen irrespective of the induction of AKT by 
hypoxia. Although clear differences between cell lines 
of the same tumor type and histology were observed, 
these data suggest that the AKT pathway is activated by 
hypoxia in HNSCC and to a lesser extent in NSCLC.
Interaction between AKT activity & hypoxic 
HIF-1 signaling is not correlated with induction 
of pAKT by hypoxia
To determine whether HIF-1 signaling under hypoxic 
conditions is regulated by the AKT pathway in the 
tested cell lines, the expression levels of HIF-1α and 
downstream proteins glucose transporter-1 (GLUT-1) 
and carbonic anhydrase IX (CAIX) were investigated 
under hypoxia with or without addition of the allosteric 
AKT inhibitor MK-2206 (Figure 2). Increased expres-
sion of HIF-1α under hypoxia was observed in all cell 
lines, which most often was followed by increased levels 
of GLUT-1 and CAIX (Figure 2). GLUT-1 and CAIX 
were not induced in all cell lines; for example, UT-
SCC24A did not show upregulation of GLUT-1, while 
HCC827 hardly showed any upregulation of CAIX. 
pAKT levels were decreased by MK-2206 during nor-
moxic and hypoxic incubation in all cell lines indicating 
effective AKT inhibition (Supplementary Figure 1).
AKT inhibition decreased the hypoxic induction of 
GLUT-1 and/or CAIX in HNSCC lines UT-SCC15, 
-24A and -38. Whereas in UT-SCC24A this was asso-
ciated with a concomitant decrease in HIF-1α, in UT-
SCC15 and -38 HIF-1α levels increased after AKT 
inhibition. In UT-SCC5 reduced hypoxic HIF-1α lev-
els were observed after AKT inhibition, but this did 
not result in reduced GLUT-1 or CAIX levels. Overall, 
no unequivocal effects of AKT inhibition on HIF-1 
signaling were found in these lines. Interaction of 
the AKT and HIF-1 pathway under hypoxia was not 
correlated with hypoxic induction of pAKT in these 
HNSCC cell lines (Figure 1A). In general, no effects 
of AKT inhibition on HIF-1 signaling were observed 
in either squamous cell carcinoma or adenocarcinoma 
NSCLC lines (Figure 2B & C). AKT inhibition only 
reduced HIF-1 and CAIX levels at 16 h of hypoxia in 
H226.
Overall, these data show that the AKT pathway 
regulates hypoxia-induced HIF-1 signaling in part 
of the HNSCC lines and that this regulation is inde-
pendent of hypoxic-induction of pAKT. No interac-
tion between the AKT pathway and hypoxia-induced 
HIF-1 signaling was observed in the NSCLC lines.
Hypoxic sensitization to AKT inhibition is 
observed in HNSCC & NSCLC lines and is 
independent of effects of AKT inhibition on 
HIF-1 signaling
We have shown before that cell survival of UT-SCC5 
and UT-SCC15 was decreased by AKT inhibition 
under hypoxic, but not normoxic conditions [9]. 
Hypoxic sensitization to AKT inhibition could be 
due to the interaction of the AKT and HIF-1 path-
way under hypoxic conditions. To test this hypothesis, 
we determined the sensitivity of our cell line panel to 
a series of MK-2206 concentrations under both nor-
moxic and hypoxic conditions (Figure 3). To determine 
whether hypoxic cells showed a higher sensitivity for 
MK-2206, cell survival after hypoxia and MK-2206 
was corrected by the effect of hypoxia alone. Signifi-
Figure 1. Induction of phosphorylation of AKT by hypoxia in head and neck squamous cell carcinoma and 
non-small-cell lung cancer cell lines (see facing page). Expression of pAKT(S473) and AKT after incubation with 
hypoxia (0.5% O2) in (A) four head and neck squamous cell carcinoma; (B) three squamous cell carcinoma non-
small-cell lung cancer and (C) three adenocarcinoma non-small-cell lung cancer cell lines. α-tubulin was used as 
loading control.
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cant differences between the effect of MK-2206 under 
normoxia and the corrected effect of MK-2206 under 
hypoxia indicate that hypoxic cells are more sensitive 
to AKT inhibition (significant differences are marked 
with asterisks in Figure 3).
As shown before, hypoxic cells of UT-SCC5 and 
UT-SCC15 were more sensitive to MK-2206 com-
pared with normoxic cells (Figure 3A). In contrast, 
UT-SCC24A and UT-SCC38 showed very low sensi-
tivity to MK-2206 under both normoxic and hypoxic 
conditions (Figure 3A). In UT-SCC24A, the survival 
of hypoxic cells was significantly higher than normoxic 
cells (p = 0.0022). Of note, this cannot be seen here, as 
cell survival is shown corrected for the effect of hypoxia 
alone. The enhanced survival after hypoxia of the UT-
SCC 24A resulted in significant enhanced sensitivity 
for MK-2206 under hypoxia at the highest doses in this 
figure. However, in absolute sense the survival of nor-
moxic and hypoxic cells was comparable at these doses. 
Squamous cell NSCLC lines H226 and SW900 also 
Figure 2. Effect of AKT inhibition on hypoxia inducible factor 1 signaling under hypoxic conditions. Expression of HIF-1α and 
downstream proteins GLUT-1 and CAIX after incubation with hypoxia (0.5% O2) with or without AKT inhibition (2 μM MK-2206) in  
(A) four HNSCC; (B) three squamous cell carcinoma NSCLC and (C) three adenocarcinoma NSCLC cell lines. α-tubulin was used as 
loading control. 
CAIS: Carbonic anhydrase IX; GLUT-1: Glucose transporter-1; HNSCC: Head and neck squamous cell carcinoma.
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Figure 3. Effect of AKT inhibition on cell survival under normoxic and hypoxic conditions. Cell survival after treatment with MK-2206 
under normoxic and hypoxic (72 h, 0.5% O2) conditions in (A) four head and neck squamous cell carcinoma; (B) three squamous cell 
carcinoma non-small-cell lung cancer and (C) three adenocarcinoma non-small-cell lung cancer cell lines. Cell survival was measured 
72 h after hypoxic incubation in head and neck squamous cell carcinoma lines and 24 h after hypoxic incubation in non-small-cell lung 
cancer lines. Cell survival under hypoxic conditions shown in graph was corrected for the effect of hypoxia alone. Error bars represent 
standard deviation. Significant synergism between hypoxia and MK-2206 was determined by correcting the cell survival after hypoxia 
and MK-2206 by the effect of hypoxia alone. Differences between the effect of MK-2206 under normoxia and the corrected effect 
of MK-2206 under hypoxia (difference = supra-additive effect) were tested for significance using Mann–Whitney tests. Significant 
enhanced sensitivity for AKT inhibition under hypoxia after bonferroni correction for multiple testing is marked with an asterisk.
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showed a higher sensitivity to MK-2206 under hypoxia 
compared with normoxia, whereas H520 cells showed 
a high sensitivity for MK-2206 independent of hypoxia 
(Figure 3B). Two adenocarcinoma NSCLC lines 
(HCC827 and H1975) showed high sensitivity and 
one (H522) low sensitivity for MK-2206 (Figure 3C). 
Although the difference was small, hypoxic H1975 cells 
did show enhanced sensitivity for MK-2206 compared 
with normoxic cells.
An overview of the data from Figure 1–Figure 3 is 
shown in Table 1. Enhanced sensitivity for AKT inhi-
bition under hypoxia was observed in part of HNSCC 
and NSCLC lines, irrespective of the effect of AKT 
inhibition on hypoxic HIF-1 signaling.
pAKT expressed in hypoxia-induced pattern in 
HNSCC, but not in NSCLC patient biopsies
Tumor biopsies from 16 HNSCC and 74 NSCLC 
patients were stained for pAKT and vessels to visual-
ize the expression pattern of pAKT. Patient charac-
teristics are shown in Table 2. Overall, the fraction of 
the tumor positive for pAKT was significantly higher 
in the squamous cell carcinomas of both the head and 
neck and lung compared with the adenocarcinomas 
of the lung (Figure 4A). In HNSCC biopsies, pAKT 
expression increased with larger distance from the 
vessels indicating that pAKT expression increased 
in areas with lower oxygen tension (Figure 4B). This 
resulted in a significant correlation between the 
relative pAKT fraction and distance from the ves-
sels (r
s
 = 0.58; p < 0.0001). In contrast, in NSCLC 
biopsies, either squamous cell or adenocarcinoma, 
pAKT expression did not increase with increasing dis-
tance from the vessels; that is, pAKT was expressed 
throughout the tumor or not (Figure 4C & D). Cor-
respondingly, no significant correlation between the 
relative pAKT fraction and distance from the vessels 
was observed in both histologies.
Discussion
Hypoxia and growth factor receptor signaling are 
known factors that cause resistance to anticancer 
treatments in solid tumors, including chemotherapy 
and radiotherapy. Reduction of these factors has the 
potential to significantly improve treatment response 
and outcome. However, strategies to reduce hypoxia 
and growth factor receptor signaling are often only 
effective in a part of the patient population. There 
are indications that the interaction between hypoxia 
and growth factor receptor signaling is impor-
tant for treatment response to these new strate-
gies [22]. Increased insight in these interactions could 
thus improve treatment choice and consequently 
treatment outcome.
The involvement of the AKT pathway in the regu-
lation of HIF-1 signaling under hypoxia is controver-
sial as contradicting results have been reported. In this 
study we investigated an extensive panel of HNSCC 
and NSCLC lines. Hypoxic induction of pAKT was 
Table 2. Tumor characteristics of patient biopsies.
Characteristic Number of tumors
Head and neck squamous cell carcinoma tumor characteristics 
Tumor site:
− Oropharynx 15
− Oral cavity 1
T classification:
− T1 0
− T2 6
− T3 5
− T4 5
N classification:
− N0 4
− N+ 12
Non-small-cell lung cancer tumor characteristics
Histology:
− Adenocarcinoma 41
− Squamous cell carcinoma 34
T classification:
− T1 27
− T2 38
− T3 4
− T4 6
N classification:
− N0 45
− N+ 30
Figure 4. Expression pattern of phosphorylation of AKT in patient biopsies from head and neck squamous cell 
carcinoma and non-small-cell lung cancer (see facing page). (A) Tumor fraction positive for pAKT in HNSCC and 
NSCLC patient biopsies. (B) Expression of pAKT in relation to vessels in biopsies from HNSCC; (C) squamous cell 
carcinoma NSCLC and (D) adenocarcinoma NSCLC patient tumors. pAKT fraction is depicted relative to the fraction 
observed within 51–100 μm zone from the nearest vessel. Zone within 50 μm from the vessels was excluded due 
to low amount of tumor cells (mostly stromal components). Microscopic images: pAKT (red), vessels (white). 
Magnification: 100×, scale bars represent 500 μm. 
HNSCC: Head and neck squamous cell carcinoma; pAKT: Phosphorylation of AKT. 
**p < 0.01.
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most often observed in the HNSCC lines, but also to a 
lesser extent in the NSCLC lines. The lack of upregula-
tion of pAKT in NSCLC could be due to the fact that 
these cell lines showed more often high pAKT levels 
under normoxic conditions, which could not be fur-
ther upregulated by hypoxia. Upregulation of pAKT 
was highest at 4–8 h of hypoxia and thereafter pAKT 
levels decreased. This downregulation of pAKT at 
later time points was also observed in cell lines that 
did not show upregulation of pAKT. Downregula-
tion of pAKT during chronic hypoxia has also been 
observed by Mottet et al. [23] in HepG2 hepatoma cells. 
In that study inhibition of the AKT pathway did result 
in decreased HIF-1α at earlier time points, but not 
at later time points. In our study we did not observe 
this biphasic effect on HIF-1α expression. However, 
we did show that the effect of AKT inhibition on 
HIF-1 signaling is not dependent on the induction of 
pAKT by hypoxia. Blancher et al. [24] similarly showed 
effects of AKT pathway inhibition on HIF-1α and 
VEGF expression during hypoxia without induction of 
pAKT by hypoxia in a panel of breast cancer cell lines. 
Downregulation of hypoxic HIF-1 signaling by AKT 
inhibition was most clearly observed in two out of four 
HNSCC lines. Only a small reduction of HIF-1 signal-
ing was observed in one out of six NSCLC lines, which 
indicates that the AKT pathway is not an important 
regulator of hypoxic HIF-1 signaling in NSCLC.
Enhanced sensitivity to AKT inhibition under 
hypoxia was observed in part of the HNSCC and 
NSCLC lines. Although regulation of HIF-1 signal-
ing by AKT was observed in HNSCC, hypoxic sensi-
tization to AKT inhibition was not correlated with the 
effect of AKT inhibition on hypoxic HIF-1 signaling. 
In contrast, hypoxic sensitization to AKT inhibition 
was, except for H1975, only observed in cell lines that 
showed upregulation of pAKT under hypoxia. This 
observation indicates that enhanced activity of the 
AKT pathway under hypoxia is important for hypoxic 
cell survival in these cell lines, but that this protec-
tive effect of AKT is independent on HIF-1 signaling. 
The AKT pathway induces multiple cell survival pro-
cesses, including inhibition of apoptosis, which results 
in improved survival under stressful conditions [25]. In 
addition, the AKT pathway interacts with the mTOR 
and the unfolded protein response pathways that 
also play a major role in hypoxic cell signaling and 
survival [26,27]. Further research will be necessary to 
determine which pathways downstream of AKT are 
important for hypoxic sensitization to AKT inhibi-
tion. As observed in this study, the interaction between 
the AKT pathway and the various pathways is likely 
to be cell-type dependent and influenced by micro-
environmental parameters like glucose concentration 
and the availability of growth factors. We can also 
not exclude that decreased HIF-1 signaling by AKT 
inhibition does play a role in the enhanced sensitiv-
ity for AKT inhibition under hypoxia in a part of our 
cell lines. Furthermore, UT-SCC38 and H522 showed 
upregulation of pAKT during hypoxia, but did not 
show enhanced sensitivity to AKT inhibition under 
hypoxia. This indicates that AKT-independent activa-
tion of downstream pathways could cause resistance to 
AKT inhibition in hypoxic cells.
Interestingly, the most of the tested HNSCC lines 
showed a relatively low sensitivity to AKT inhibition, 
while some NSCLC showed a very high sensitivity 
to AKT inhibition. The NSCLC lines showing high 
sensitivity to AKT inhibition, that is, H520, HCC827 
and H1975, have also the highest basal pAKT lev-
els. The high activity of AKT thus seems to reflect a 
dependence on the AKT pathway for cell survival in 
these cell lines. In the NSCLC lines with low basal 
pAKT levels that induced pAKT under hypoxia, that 
is, H226 and SW900, showed enhanced sensitiza-
tion to AKT inhibition under hypoxia indicating that 
the importance of the AKT pathway for cell survival 
can become larger under stressful conditions. In the 
HNSCC lines the constitutive expression of pAKT 
was not correlated with sensitivity for AKT inhibi-
tion. This discrepancy between the NSCLC and 
HNSCC lines could be due to a differential genetic 
background. In general, NSCLC have more often acti-
vating mutations in important growth factor receptor 
signaling genes like EGFR and KRAS, although the 
percentage is lower in squamous cell NSCLC com-
pared with adenocarcinoma NSCLC [28,29]. These acti-
vating mutations can result in ‘oncogene addiction’, 
which can make a tumor cell very sensitive to inhi-
bition under control conditions. The AKT pathway 
is an important downstream pathway of both EGFR 
and KRAS and cell lines with mutations in these genes 
could thus also be dependent on AKT signaling. We 
have not performed mutational analysis in our cell 
panel, but it is for example known that H1975 and 
HCC827, both very sensitive for AKT inhibition, have 
activating mutations in EGFR [30]. Consistent with 
the in vitro results pAKT was expressed in a hypoxia-
related pattern in the HNSCC biopsies. These results 
confirm our previous observations in larger cohorts of 
HNSCC patients [8,31]. Hypoxic induction of pAKT 
was only observed in two out of six NSCLC lines. In 
some NSCLC biopsies a hypoxia-related pAKT expres-
sion was visible, but as this was not a general expres-
sion pattern there was no overall correlation between 
the pAKT expression and distance from the vessels 
observed in this patient population. Hence, our in vitro 
observations do seem to reflect the clinical situation.
www.future-science.com 10.4155/fso.15.84future science group
Interaction between hypoxia, AKT & HIF-1 signaling in HNSCC & NSCLC    Research Article
The observed differences in the interaction between 
hypoxia, AKT and HIF-1 signaling between tumors 
of different origin and histology could have important 
consequences for patient selection for AKT inhibi-
tion and hypoxic modification. Our data show that 
high AKT expression in NSCLC, either present due 
to mutational changes or induced by hypoxia, is cor-
related with high sensitivity to AKT inhibition. This 
suggests that AKT inhibition is a promising target to 
improve outcome in NSCLC patients with high pAKT 
expression. Moreover, NSCLC patients with hypoxic 
tumors could additionally benefit from hypoxic modi-
fication or HIF-1 inhibition, as there was no interac-
tion between AKT and HIF-1 signaling in this tumor 
type. Hypoxic HNSCC cells that upregulated pAKT 
showed the highest sensitivity to AKT inhibition 
indicating that AKT inhibition could be beneficial in 
HNSCC patients with pAKT expressed in a hypoxia-
related pattern. AKT inhibition, however, was not suc-
cessful in all HNSCC lines that upregulated pAKT 
under hypoxia and further research will be necessary 
to find additional tumor characteristics that could pre-
dict for treatment response to AKT inhibition under 
hypoxia to identify this patient group.
Conclusion
The interaction between hypoxia, AKT activation 
and HIF-1 signaling varies widely between tumor 
types and cell lines of the same tumor type. In the 
cell lines tested here, an interaction between AKT 
signaling and hypoxic HIF-1 signaling was observed 
in squamous cell carcinoma of the head and neck, but 
not in squamous cell or adenocarcinomas of the lung. 
However, this variation could not explain the differen-
tial response to AKT inhibition under normoxic and 
hypoxic conditions. Further research will be necessary 
to identify which pathways are critical for response 
to both targeted therapies like AKT inhibition and 
hypoxic modification. Only in this way predictive bio-
markers can be identified and patient selection can be 
optimized to obtain the best clinical outcome for each 
individual patient.
Future perspective
Increasing insight in mechanisms that induce resis-
tance to anticancer treatments in solid tumors has led 
to the development of various therapies that specifically 
target these resistance mechanisms. However, clinical 
success is often reduced because these strategies are only 
effective in a part of the patient population. Hence, 
insight in the factors that influence treatment effec-
tiveness could help to optimize patient selection and 
consequently patient outcome. This study investigated 
the interaction between hypoxia, HIF-1 and AKT 
signaling, which are tumor factors that could play an 
important role in the response to hypoxic modification 
and AKT pathway inhibitors. We show that this inter-
action varies widely between tumor types and cell lines 
of the same tumor type. These differences could affect 
treatment response to various anticancer strategies sig-
nificantly. Our observations underwrite the high varia-
tion in critical tumor characteristics and importance 
for future research into predictive biomarkers. Only in 
this way patient selection can be optimized, which will 
significantly increase the chance on clinical success of 
newly developed anticancer therapies.
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